SCHEMBL2865476

SCHEMBL2865476

CCC(C(=O)OC)c1cc(O)cc(O)c1C(=O)c1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC5A1 P13866 3/20 0.46
SLC5A2 P31639 3/20 0.46
HPGD P15428 1/20 0.42
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
SYNJ2 O15056 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
AKR1C3 P42330 3/20 0.40
AKR1C2 P52895 3/20 0.40
AKR1C1 Q04828 1/20 0.40
PTGS1 P23219 1/20 0.40
MAPT P10636 1/20 0.40
SLC22A12 Q96S37 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861398 0.91 NR1H2 (0.44) CYP3A4NR1H2NR1H3SYNJ2PTGS1
SCHEMBL2861279 0.89 AKR1C3 (0.50) CYP3A4CYP2D6CYP2C19SLC5A1SLC5A2
SCHEMBL2861765 0.88 NR1H2 (0.41) CYP3A4SLC5A1SLC5A2NR1H2NR1H3
SCHEMBL2861697 0.88 TRPV1 (0.42) CYP3A4CYP2D6CYP2C19HPGDNR1H2
SCHEMBL2860488 0.87 TAS1R3 (0.44) CYP3A4CYP2D6CYP2C19HPGDMAPT
SCHEMBL2860149 0.86 SYNJ2 (0.51) CYP3A4CYP2D6CYP2C19HPGDNR1H2
SCHEMBL2865026 0.85 LDHA (0.45) CYP3A4NR1H2NR1H3SYNJ2PTGS1
SCHEMBL2861256 0.84 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C19HPGDNR1H2
SCHEMBL2856271 0.83 TAS1R3 (0.46) CYP3A4CYP2D6CYP2C19HPGDNR1H2
SCHEMBL2862135 0.82 CYP2D6 (0.45) CYP3A4CYP2D6CYP2C19SLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP claimed
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP disclosed
US-7767693-B2 Hsp90 family protein inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-08-03 US disclosed
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-10-01 US disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 US disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P CYP3A4 2051/4885CYP2D6 1825/4885CYP2C19 1259/4885
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS HSP90AB1, HSP90B1, HSP90AB2P CYP3A4 2051/4885CYP2D6 1825/4885CYP2C19 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.